Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258180 · ClinicalTrials.gov registry record · Phase 2
Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00258180: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT00258180 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00258180, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Cyclophosphamide may help control the symptoms of autoimmune enteropathy . PURPOSE: This phase II trial is studying how well cyclophosphamide works in treating young patients with severe autoimmune enteropathy.
Primary Outcome
Number of participants off therapy 1 year after study completion without relapse.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2005-08-15 |
| Est. Completion | 2009-02-24 |
| Phase | Phase 2 |
What the finished NCT00258180 record still lists
NCT00258180 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which cyclophosphamide is the first listed.
NCT00258180 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00258180 about?
NCT00258180 is a clinical study titled "Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy". RATIONALE: Cyclophosphamide may help control the symptoms of autoimmune enteropathy . PURPOSE: This phase II trial is studying how well cyclophosphamide works in treating young patients with severe autoimmune enteropathy.
What is the current status of trial NCT00258180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2005-08-15. Estimated completion is 2009-02-24.
What interventions are being tested in trial NCT00258180?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00258180?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00258180's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI